Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

G.D. Searle LLC v. Lupin Pharmaceuticals, Inc., No. 14-1476 (Fed. Cir. June 23, 2015)

Affirmed
Invalidity (§ 102/§ 103) Claim Construction
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 14-1476
Decided
June 23, 2015
Judge
Bryson, J.
Document
Precedential Opinion
Length
14 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

G.D. Searle LLC and Pfizer Asia Pacific Pte. Ltd. (col- lectively, “Pfizer”) appeal from a final judgment entered by the United States District Court for th e Eastern Di s- trict of Virginia. The court invalidated the relevant claims of Pfizer’s reissued U.S. Patent No. RE44,048 (“the G.D. SEARLE LLC v. LUPIN PHARMACEUTICALS, INC. 3 RE ’048 patent”) f or obviousness -type double patenting . We affirm.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error